Sex and gender differences in hematology

Sex and Gender Aspects in Clinical Medicine

Volumn , Issue , 2013, Pages 151-168

  Schmetzer, Oliver ^a   Flörcken, Anne ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926401427     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-85729-832-4_10     Document Type: Chapter

References (81)

1. Cook JD, Finch CA, Smith NJ. Evaluation of the iron status of a population. Blood. 1976;48(3):449.
2. Looker AC, Dallman PR, Carroll MD, Gunter EW, Johnson CL. Prevalence of iron deficiency in the United States. JAMA. 1997;277(12):973.
3. Brittenham G. Disorders of iron metabolism: iron deficiency and overload. In: Hoffman R, Benz EJ Jr, Shattil SJ, et al., eds. Hematology Basic Principles and Practice. New York: Churchill Livingstone; 2005:481.
4. El-Maarri O, Becker T, Junen J, et al. Gender specific differences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher methylation levels in males. Hum Genet. 2007;122(5):505.
5. Merkel D, Moran DS, Yanovich R, et al. The association between hematological and inflammatory factors and stress fractures among female military recruits. Med Sci Sports Exerc. 2008;40(11 Suppl):S691.
6. Bain Barbara J. Blood Cells. A Practical Guide. London: Blackwell Science; 2002.
7. Nordin G, Martensson A, Swolin B, et al. A multicentre study of reference intervals for haemoglobin, basic blood cell counts and erythrocyte indices in the adult population of the Nordic countries. Scand J Clin Lab Invest. 2004;64(4):385.
8. Guyatt GH, Oxman AD, Ali M, Willan A, McIlroy W, Patterson C. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med. 1992;7(2):145.
9. Punnonen K, Irjala K, Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood. 1997;89(3):1052.
10. Steinberg MH, Hsu H, Nagel RL, et al. Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia. Am J Hematol. 1995;48(3):175.
11. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int. 2001;59(2):725.
12. Crooks CJ, West J, Solaymani-Dodaran M, Card TR. The epidemiology of haemochromatosis: a population-based study. Aliment Pharmacol Ther. 2009;29(2):183.
13. Burke W, Thomson E, Khoury MJ, et al. Hereditary hemochromatosis: gene discovery and its implications for populationbased screening. JAMA. 1998;280(2):172.
14. Deugnier Y, Jouanolle AM, Chaperon J, et al. Genderspecific phenotypic expression and screening strategies in C282Y-linked haemochromatosis: a study of 9396 French people. Br J Haematol. 2002;118(4):1170.
15. Lidegaard O, Kreiner S. Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception. 2002;65(3):197.
16. Lidegaard O. Thrombotic diseases in young women and the influence of oral contraceptives. Am J Obstet Gynecol. 1998;179(3 Pt 2):S62.
17. Roeloffzen WW, Kluin-Nelemans HC, Mulder AB, Veeger NJ, Bosman L, De Wolf JT. In normal controls, both age and gender affect coagulability as measured by thrombelastography. Anesth Analg. 2010;110(4):987.
18. Gorton HJ, Warren ER, Simpson NA, Lyons GR, Columb MO. Thromboelastography identifies sex-related differences in coagulation. Anesth Analg. 2000;91(5):1279.
19. Cahill M, Mistry R, Chapman C, Wood JK, Barnett DB. Effects of age, sex and the oral contraceptive on the platelet membrane fibrinogen binding site (glycoprotein IIb/IIIa). Br J Clin Pharmacol. 1992;33(1):11.
20. Tsang CW, Lazarus R, Smith W, Mitchell P, Koutts J, Burnett L. Hematological indices in an older population sample: derivation of healthy reference values. Clin Chem. 1998;44(1):96.
21. Moysidis T, Kroger K, Moerchel C, Santosa F, Grochenig E. Pulmonary embolism in young males and females in Germany: data from the Federal Statistical Office. Blood Coagul Fibrinolysis. 2010;21(6):511.
22. Kroger K, Moerchel C, Moysidis T, Santosa F. Incidence rate of pulmonary embolism in Germany: data from the federal statistical office. J Thromb Thrombolysis. 2010;29(3):349.
23. Blanco-Molina A, Trujillo-Santos J, Tirado R, et al. Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost. 2009;101(3):478.
24. Sakuma M, Nakamura M, Takahashi T, et al. Pulmonary embolism is an important cause of death in young adults. Circ J. 2007;71(11):1765.
25. Stein PD, Huang H, Afzal A, Noor HA. Incidence of acute pulmonary embolism in a general hospital: relation to age, sex, and race. Chest. 1999;116(4):909.
26. Laczkovics C, Grafenhofer H, Kaider A, et al. Risk of recurrence after a first venous thromboembolic event in young women. Haematologica. 2007;92(9):1201.
27. Warkentin TE, Sheppard JA, Sigouin CS, Kohlmann T, Eichler P, Greinacher A. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood. 2006;108(9):2937.
28. Levi F, Lucchini F, Negri E, La Vecchia C. Cancer mortality in the European Union, 1988-1997: the fall may approach 80, 000 deaths a year. Int J Cancer. 2002;98(4):636.
29. Molica S. Sex differences in incidence and outcome of chronic lymphocytic leukemia patients. Leuk Lymphoma. 2006;47(8):1477.
30. Kravdal O, Hansen S. Hodgkin's disease: the protective effect of childbearing. Int J Cancer. 1993;55(6):909.
31. Chen WY, Zeng X, Carter MG, et al. Heterozygous disruption of Hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet. 2003;33(2):197.
32. Hu W, Feng Z, Teresky AK, Levine AJ. p53 regulates maternal reproduction through LIF. Nature. 2007;450(7170):721.
33. Hu W, Feng Z, Atwal GS, Levine AJ. p53: a new player in reproduction. Cell Cycle. 2008;7(7):848.
34. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317(5834):121.
35. Sander LE, Trautwein C, Liedtke C. Is interleukin-6 a genderspecific risk factor for liver cancer? Hepatology. 2007;46(4):1304.
36. Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol. 2008;48(2):380.
37. Balbin M, Fueyo A, Tester AM, et al. Loss of collagenase-2 confers increased skin tumor susceptibility to male mice. Nat Genet. 2003;35(3):252.
38. Gazzeri R, Galarza M, Gazzeri G. Growth of a meningioma in a transsexual patient after estrogen-progestin therapy. N Engl J Med. 2007;357(23):2411.
39. Mossuz P, Cousin F, Castinel A, et al. Effects of two sex steroids (17beta estradiol and testosterone) on proliferation and clonal growth of the human monoblastic leukemia cell line, U937. Leuk Res. 1998;22(11):1063.
40. Durcova-Hills G, Hajkova P, Sullivan S, Barton S, Surani MA, McLaren A. Influence of sex chromosome constitution on the genomic imprinting of germ cells. Proc Natl Acad Sci USA. 2006;103(30):11184.
41. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010;42(4):338.
42. Bolufer P, Collado M, Barragan E, et al. The potential effect of gender in combination with common genetic polymorphisms of drug-metabolizing enzymes on the risk of developing acute leukemia. Haematologica. 2007;92(3):308.
43. Cartwright RA, Gurney KA, Moorman AV. Sex ratios and the risks of haematological malignancies. Br J Haematol. 2002;118(4):1071.
44. Jentsch-Ullrich K, Koenigsmann M, Mohren M, Franke A. Lymphocyte subsets' reference ranges in an age- and genderbalanced population of 100 healthy adults - a monocentric German study. Clin Immunol. 2005;116(2):192.
45. Glaser SL, Clarke CA, Nugent RA, Stearns CB, Dorfman RF. Reproductive factors in Hodgkin's disease in women. Am J Epidemiol. 2003;158(6):553.
46. Pui CH, Boyett JM, Relling MV, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol. 1999;17(3):818.
47. Robak T, Szmigielska-Kaplon A, Wrzesien-Kus A, et al. Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience. Ann Hematol. 2004;83(4):225.
48. Somigliana E, Vigano P, Vignali M. Endometriosis and unexplained recurrent spontaneous abortion: pathological states resulting from aberrant modulation of natural killer cell function? Hum Reprod Update. 1999;5(1):40.
49. Allgar VL, Neal RD. Delays in the diagnosis of six cancers: analysis of data from the National Survey of NHS Patients: cancer. Br J Cancer. 2005;92(11):1959.
50. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329(14):987.
51. Coiffier B, Gisselbrecht C, Vose JM, et al. Prognostic factors in aggressive malignant lymphomas: description and validation of a prognostic index that could identify patients requiring a more intensive therapy. The Groupe d'Etudes des Lymphomes Agressifs. J Clin Oncol. 1991;9(2):211.
52. Osby E, Askling J, Landgren O, Dickman PW, Ekbom A, Bjorkholm M. Parental longevity and prognosis in elderly patients with aggressive non-Hodgkin's lymphoma. Acta Oncol. 2004;43(3):297.
53. Hasselblom S, Ridell B, Nilsson-Ehle H, Andersson PO. The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma - a populationbased study. Leuk Lymphoma. 2007;48(4):736.
54. Burkhardt B, Zimmermann M, Oschlies I, et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol. 2005;131(1):39.
55. Catovsky D, Matutes E, Dearden C, Osuji N, Brito-Babapulle V. The WHO classification of mature T-cell leukemias. Blood. 2004;104(9):2989.
56. Wohl Y, Golan H, Brenner S. Cutaneous lymphomas and association to sex hormones. Skinmed. 2003;2(5):312.
57. Gregersen H, Mellemkjaer L, Ibsen JS, Dahlerup JF, Thomassen L, Sorensen HT. The impact of M-component type and immunoglobulin concentration on the risk of malignant transforma tion in patients with monoclonal gammopathy of undetermined significance. Haematologica. 2001;86(11):1172.
58. Sokal JE, Baccarani M, Tura S, et al. Prognostic discrimination among younger patients with chronic granulocytic leukemia: relevance to bone marrow transplantation. Blood. 1985;66(6):1352.
59. Lee JP, Birnstein E, Masiello D, Yang D, Yang AS. Gender and ethnic differences in chronic myelogenous leukemia prognosis and treatment response: a single-institution retrospective study. J Hematol Oncol. 2009;2:30.
60. Berger U, Maywald O, Pfirrmann M, et al. Gender aspects in chronic myeloid leukemia: long-term results from randomized studies. Leukemia. 2005;19(6):984.
61. Ribeiro RC, Razzouk BI, Pounds S, Hijiya N, Pui CH, Rubnitz JE. Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000. Leukemia. 2005;19(12):2125.
62. Bhayat F, Das-Gupta E, Smith C, McKeever T, Hubbard R. The incidence of and mortality from leukaemias in the UK: a general population-based study. BMC Cancer. 2009;9:252.
63. Wong O, Harris F, Yiying W, Hua F. A hospital-based casecontrol study of acute myeloid leukemia in Shanghai: analysis of personal characteristics, lifestyle and environmental risk factors by subtypes of the WHO classification. Regul Toxicol Pharmacol. 2009;55(3):340.
64. Meistrich ML, Shetty G. Hormonal suppression for fertility preservation in males and females. Reproduction. 2008;136(6):691.
65. Horning SJ, Hoppe RT, Kaplan HS, Rosenberg SA. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med. 1981;304(23):1377.
66. Tao T, Del Valle A. Human oocyte and ovarian tissue cryopreservation and its application. J Assist Reprod Genet. 2008;25(7):287.
67. Varghese AC, Du Plessis SS, Falcone T, Agarwal A. Cryopreservation/transplantation of ovarian tissue and in vitro maturation of follicles and oocytes: challenges for fertility preservation. Reprod Biol Endocrinol. 2008;6:47.
68. Pavlidis NA. Coexistence of pregnancy and malignancy. Oncologist. 2002;7(4):279.
69. Azim HA Jr, Pavlidis N, Peccatori FA. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: hematological tumors. Cancer Treat Rev. 2010;36(2):110.
70. Jones PR, Wilkinson S, Davies PS. A revision of body surface area estimations. Eur J Appl Physiol Occup Physiol. 1985;53(4):376.
71. Marosi C. Gender aspects of treatment and drug related toxicity in medical oncology. Wien Med Wochenschr. 2006;156(19-20):534.
72. Dobbs NA, Twelves CJ, Gillies H, James CA, Harper PG, Rubens RD. Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry. Cancer Chemother Pharmacol. 1995;36(6):473.
73. Wade JR, Kelman AW, Kerr DJ, Robert J, Whiting B. Variability in the pharmacokinetics of epirubicin: a population analysis. Cancer Chemother Pharmacol. 1992;29(5):391.
74. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer. 2000;82(5):1013.
75. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 2008;14(2):85.
76. Jann MW, Zum Brunnen TL, Tenjarla SN, Ward ES Jr, Weidler DJ. Relative bioavailability of ondansetron 8-mg oral tablets versus two extemporaneous 16-mg suppositories: formulation and gender differences. Pharmacotherapy. 1998;18(2):288.
77. Tsavaris N, Fountzilas G, Mylonakis N, et al. A randomized comparative study of antiemetic prophylaxis with ondansentron in a single 32-mg loading dose versus 8 mg every 6 h in patients undergoing cisplatin-based chemotherapy. Oncology. 1998;55(6):513.
78. Osoba D, Zee B, Pater J, Warr D, Latreille J, Kaizer L. Determinants of postchemotherapy nausea and vomiting in patients with cancer. Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1997;15(1):116.
79. Hartvig Honore P. Molecular mechanisms in cytotoxic drug induced fatigue. Ann Pharm Fr. 2010;68(2):76.
80. Goldberg SL, Chiang L, Selina N, Hamarman S. Patient perceptions about chemotherapy-induced oral mucositis: implications for primary/secondary prophylaxis strategies. Support Care Cancer. 2004;12(7):526.
81. Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number Tomudex International Study Group. Eur J Cancer. 1998;34(12):1871.